You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT06083675 ↗ Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes Withdrawn Novo Nordisk A/S Phase 3 2024-01-26 This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when they are taking the study medicines. Participants will either get semaglutide tablets, empagliflozin tablets or metformin tablets. Which treatment participants will get is decided by chance. Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsus) can be prescribed in some countries. 25 mg and 50 mg semaglutide tablets are new doses. 10 mg and 25 mg empagliflozin tablets (Jardiance) can be prescribed in some countries. 500 mg metformin tablets (STADA) can be prescribed in some countries. Participants will get 1 to 4 tablets per day for 104 weeks. The study will last for about 2 years and 7 weeks (111 weeks). Participants should not have been treated for weight management 90 days before screening or never been treated with any medicine for type 2 diabetes (except diabetes during pregnancy) before screening. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01001962 ↗ Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics Unknown status Aristotle University Of Thessaloniki Phase 4 2016-01-01 Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects receiving EMPAGLIFLOZIN 3. Reduction in the total cardiovascular risk 4. 3 years morbidity and mortality rates 5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving EMPAGLIFLOZIN
NCT01159600 ↗ Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2010-07-01 The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
NCT01159600 ↗ Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 2010-07-01 The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
NCT01167881 ↗ Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2010-08-01 This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.
NCT01167881 ↗ Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 2010-08-01 This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.
NCT01210001 ↗ Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin Completed Eli Lilly and Company Phase 3 2010-09-01 This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to pioglitazone alone or in combination with metformin.
NCT01210001 ↗ Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin Completed Boehringer Ingelheim Phase 3 2010-09-01 This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients in order to provide these data for approval for BI 10773 by regulatory authorities as an antidiabetic agent as add-on therapy to pioglitazone alone or in combination with metformin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Condition Name

Condition Name for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Intervention Trials
Diabetes Mellitus, Type 2 18
Healthy 15
Type 2 Diabetes Mellitus 5
Diabetes Mellitus 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Intervention Trials
Diabetes Mellitus 39
Diabetes Mellitus, Type 2 38
Non-alcoholic Fatty Liver Disease 5
Fatty Liver 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Trials by Country

Trials by Country for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Location Trials
United States 225
Canada 50
India 20
Germany 19
Australia 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Location Trials
Texas 15
Florida 12
Georgia 11
California 11
North Carolina 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 16
Phase 3 18
Phase 2/Phase 3 4
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 38
Recruiting 15
Not yet recruiting 7
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Sponsor Name

Sponsor Name for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Sponsor Trials
Boehringer Ingelheim 26
Eli Lilly and Company 17
Medanta, The Medicity, India 4
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Sponsor Trials
Industry 61
Other 57
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.